Tata Elxsi Opens Offshore Development Center for Japan's Terumo Corporation

Tata Elxsi and Terumo Corporation inaugurated a dedicated Offshore Development Center (ODC) in Pune, India, on March 19, 2026, marking a significant expansion of the two companies' collaborative footprint in medical device development. The facility, named the Terumo–Tata Elxsi Offshore Development Center, will support the full spectrum of product development for Terumo's cardiovascular portfolio, spanning engineering, design, verification, regulatory compliance, localisation, and continuous lifecycle management across international markets.

The center brings together multidisciplinary teams with the aim of consolidating several critical functions under one dedicated operation. By integrating design, engineering, and compliance expertise in a single offshore facility, both companies indicated they expect to shorten development cycles and respond more effectively to the varying regulatory and market requirements of different geographies.

A notable aspect of the arrangement is its planned use of artificial intelligence and generative AI within software engineering workflows. Tata Elxsi stated that these technologies would be applied to accelerate development and enable regional adaptation of products, while also addressing rising demand for patient-centric medical devices at competitive price points. The company positioned AI and GenAI not as experimental tools but as functional components of its engineering delivery model.

Fumihisa Hirose, Company President of Terumo's Cardiac & Vascular division, said the center would strengthen the company's capacity to bring high-quality medical technologies to global markets more quickly. He specifically cited Tata Elxsi's integrated design, engineering, and regulatory expertise as central to Terumo's strategy for accelerating its global product roadmap while maintaining safety and compliance standards.

Sreevatsa Sahasranaman, Senior Vice President and Head of Healthcare & Life Sciences at Tata Elxsi, described the ODC as a comprehensive, long-term partnership model. He said the center would apply deep domain expertise across Terumo's cardiovascular range, with a focus on driving innovation and cost efficiencies, and on helping the company reach both established and emerging markets with next-generation medical technologies.

Terumo Corporation is a Japan-headquartered global medical device company with a broad product portfolio spanning blood management, cardiovascular intervention, diabetes care, and hospital systems. Its Cardiac & Vascular division develops technologies used in interventional cardiology and vascular surgery, areas where device reliability, regulatory precision, and localisation for varied healthcare systems are particularly demanding requirements.

Tata Elxsi, listed on the BSE and NSE under the scrip code TATAELXSI, is a design and technology services company headquartered in Bangalore. It operates across the healthcare, automotive, broadcast, and communications sectors through a network of design studios, development centers, and innovation hubs. Its Healthcare & Life Sciences division holds ISO 13485 certification, the internationally recognised standard for quality management systems in the medical device industry, and works with global medical device and pharmaceutical companies on product development across the product lifecycle.

The partnership reflects a broader trend of global medical device companies establishing dedicated offshore engineering centers in India, drawn by a combination of technical talent, cost advantages, and growing regulatory expertise. India has increasingly become a destination for high-complexity engineering work in regulated industries, moving beyond earlier models focused primarily on cost reduction.

The disclosure was filed with the BSE and NSE on March 19, 2026, by Tata Elxsi's Company Secretary and Compliance Officer, Sneha V, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates that listed entities promptly disclose material developments to the exchanges.